Flibanserin Approval: Facts or Feelings?

Autor: James A. Simon, MD, CCD, NCMP, IF, FACOG, Irwin Goldstein, MD, Noel N. Kim, PhD, Murray A. Freedman, MS, MD, FACOG, Sharon J. Parish, MD, NCMP, IF

Publikováno v: Sexual Medicine, Vol 4, Iss 2, Pp e69-e70 (2016)

Externí odkaz: https://doaj.org/article/45c2ffca22134c00a443a7b911655200

Randomized controlled trial of interferon-beta-1a in secondary progressive MS - Clinical results

Autor: King, J, McLeod, J, Gonsette, R, Duquette, P, Ebers, G, Rice, G, Francis, G, Lapierre, Y, Freedman, MS, Oger, J, Paty, D, Sorensen, P, Pelletier, J, Hommes, O, Jongen, P, Sanders, E, Andersen, O, Wollheim-Sandberg, M, Chofflon, M, Bates, D, Barnes, D, Blumhardt, L, Hawkins, C, Hughes, R, Palace, J

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::cbbd4caf9a35c6ccc9ef8b758be5ca74
https://doi.org/10.1212/wnl.56.11.1496

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

Autor: Patsopoulos NA, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán X, Polman CH, Freedman MS, Hartung HP, Arnason BGW, COMI , GIANCARLO, Cook S, FILIPPI , MASSIMO, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk J, Hillert J, Bahlo M, Booth DR, BroadleyS, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi F, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PIW, the BSP MS Genetics working group, the steering committees of studies evaluating IFNb 1b, a. CCR1 antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium

Publikováno v: Annals of Neurology, 70(6), 897-912. John Wiley and Sons Inc.
Patsopoulos, N A, Bakker, P I W & Polman, C H 2011, ' Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci ', Annals of Neurology, vol. 70, no. 6, pp. 897-912 . https://doi.org/10.1002/ana.22609

OBJECTIVE: To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci. METHODS: We synthesized 7 MS GWAS. Each data set was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef8585134ddd788a2ca78fc05301762
https://doi.org/10.1002/ana.22609

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Autor: Paul, O'Connor, Wolinsky, Jerry S., Christian, Confavreux, Giancarlo, Comi, Ludwig, Kappos, Olsson, Tomas P., Hadj, Benzerdjeb, Philippe, Truffinet, Lin, Wang, Aaron, Miller, Temso Trial Group Reingold, Freedman Ms S., Cutter, G., Antel, J., Barkhof, F., Maddrey, W., Ravnborg, M., Schenker, S., O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Miller, A., Freedman, Mark S., Narayana, P. A., Nelson, F., Vainrub, I., Datta, S., He, R., Gates, B., Ton, K., Wamil, B., Truffinet, P., Igau, B., Nicolas, V., Notelet, L., Payrard, S., Wijnand, P., Devore, S., H. H., Li, Osho, T., Wang, L., Wei, L., Dukovic, D., Ling, Y., Benzerdjeb, H., Mednikova, Z., Trabelsi, N., Musset, M., Merrill, D., Turpault, S., Williams, B., Nortmeyer, H., Kirst, E., Witthaus, E., Chen, S., Maida, E., Auff, E., Fazekas, F., Berger, T., Bhan, V., Bouchard, J. P., Duquette, P., Freedman, M., Grand'Maison, F., Kremenchutzky, M., Bourque, C., Marrie, R. A., Melanson, M., Patry, D., Oger, J., Stefanelli, M., Jacques, F., Venegas, P., Miranda, M., Barrientos, N., Tenhamm, E., Gloger, S., Rohde, G., Mares, J., Frederiksen, J., Stenager, E., Haldre, S., Gross Paju, K., Elovaara, I., Sumelahti, M. L., Erälinna, J. P., Farkkila, M., Harno, H., Reunanen, M., Jolma, T., Camu, W., Clavelou, P., Magy, L., Debouverie, M., Edan, G., Lebrun Frenay, C., Moreau, T., Pelletier, J., Roullet, E., Alamowitch, S., Clanet, M., Hautecoeur, P., Damier, P., Rumbach, L., Chan, A., Schimrigk, S., Haas, J., Lensch, E., Diener, H., Limmroth, V., Anders, D., Berghoff, M., Oschmann, P., Stangel, M., Frese, A., Kiefer, R., Marziniak, M., Zettl, U., Stark, E., Jendroska, K., Reifschneider, G., Amato, M. P., Cosi, V., Gallo, P., Gasperini, Claudio, Ghezzi, A., Trojano, M., Pozzilli, Carlo, Montanari, E., Zwanikken, C. P., Jongen, P. J., Van Munster, E. T., Hupperts, R. M., Anten, B., Sanders, E. A., Celius, E., Hovdal, H., Krogseth, S. B., Kozubski, W., Kwiecinski, H., Czlonkowska, A., Stelmasiak, Z., Selmaj, K., Hasiec, T., Fryze, W., Drozdowski, W., Kochanowicz, J., Cunha, L., De Sa, J., Sena, A. H., Odinak, M., Skoromets, A., Gusev, E., Boiko, A., Lashch, N., Stolyarov, I., Belova, A., Malkova, N., Doronin, B., Yakupov, E., Brundin, L., Hillert, J., Karabudak, R., Irkec, C., Idiman, E., Turan, O., Efendi, H., Gedizlioglu, M., Buchakchyyska, N., Goloborodko, A., Ipatov, A., Kobets, S., Lebedynets, V., Moskovko, S., Sanotskyy, Y., Smolanka, V., Yavorskaya, V., Bates, D., Evangelou, N., Hawkins, C., Mclean, B., O'Riordan, J., Price, S., Turner, B., Barnes, D., Zajicek, J., Honeycutt, W., Khan, O., Spikol, L., Stevens, J.

Publikováno v: Wolinsky, J S, Confavreux, C, Comi, G, Kappos, L, Olsson, T P, Benzerdjeb, H, Truffinet, P, Wang, L, Miller, A E, Freedman, M S, Stenager, E & Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group 2011, ' Randomized trial of oral teriflunamide for relapsing multiple sclerosis ', The New England Journal of Medicine, vol. 2011, no. 365, pp. 1293-1303 . https://doi.org/10.1056/NEJMoa1014656
New England Journal of Medicine, 365(14), 1293-1303. MASSACHUSETTS MEDICAL SOCIETY

Teriflunomide reduced the annualized relapse rate (0.54 for placebo vs. 0.37 for teri flunomide at either 7 or 14 mg), with relative risk reductions of 31.2% and 31.5%, respectively (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea72b10598dc98c42c6663d5f5508b91
https://doi.org/10.1056/nejmoa1014656

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

Autor: Leist TP, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset Semanaz F, Scaramozza M, oral cladribine for early MS Study Group, COMI , GIANCARLO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10495::35bf9a8bd5150925af2f8adfb787f9bb